ReviewClinical reviews in allergy & immunology2008
Gene therapy for cystic fibrosis.
Review in Clinical reviews in allergy & immunology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Diagnosis and treatment of cystic fibrosis in India: What is at stake for developing countries?Journal of biosciences · 2024Review
- Short-Term Steroid Treatment of Rhesus Macaque Increases Transduction.Human gene therapy · 2022Article
- Article
- Transduction of Surface and Basal Cells in Rhesus Macaque Lung Following Repeat Dosing with AAV1CFTR.Human gene therapy · 2020Article
- Conventional and Nanotechnology Based Approaches to Combat Chronic Obstructive Pulmonary Disease: Implications for Chronic Airway Diseases.International journal of nanomedicine · 2020Review
- Restoration of F508-del Function by Transcomplementation: The Partners Meet in the Endoplasmic Reticulum.Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology · 2019Article
- Suppression of IGF1R in Melanoma Cells by an Adenovirus-Mediated One-Step Knockdown System.Molecular therapy. Nucleic acids · 2018Article
- Cystic fibrosis lung environment and Pseudomonas aeruginosa infection.BMC pulmonary medicine · 2016Review
- Optimization of Recombinant Adeno-Associated Virus-Mediated Expression for Large Transgenes, Using a Synthetic Promoter and Tandem Array Enhancers.Human gene therapy · 2015Article
- Hybrid nonviral/viral vector systems for improved piggyBac DNA transposon in vivo delivery.Molecular therapy : the journal of the American Society of Gene Therapy · 2015Article
- Ferret and pig models of cystic fibrosis: prospects and promise for gene therapy.Human gene therapy. Clinical development · 2015Review
- Testing gene therapy vectors in human primary nasal epithelial cultures.Molecular therapy. Methods & clinical development · 2015Article
- Overcoming the cystic fibrosis sputum barrier to leading adeno-associated virus gene therapy vectors.Molecular therapy : the journal of the American Society of Gene Therapy · 2014Article
- A novel chimeric adenoassociated virus 2/human bocavirus 1 parvovirus vector efficiently transduces human airway epithelia.Molecular therapy : the journal of the American Society of Gene Therapy · 2013Article
- Reduced Arylsulfatase B activity in leukocytes from cystic fibrosis patients.Pediatric pulmonology · 2013Article
- A novel pancreatropic coxsackievirus vector expressing glucagon-like peptide 1 reduces hyperglycemia in streptozotocin-treated mice.Journal of virology · 2011Article
- N-acetylcysteine enhances cystic fibrosis sputum penetration and airway gene transfer by highly compacted DNA nanoparticles.Molecular therapy : the journal of the American Society of Gene Therapy · 2011Article
- PEGylation improves nanoparticle formation and transfection efficiency of messenger RNA.Pharmaceutical research · 2011Article
- Whole genome amplification in preimplantation genetic diagnosis.Journal of Zhejiang University. Science. B · 2011Review
- Nebulisation of receptor-targeted nanocomplexes for gene delivery to the airway epithelium.PloS one · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Cystic Fibrosis (CF) is an autosomal recessive disorder due to mutations in the CF transmembrane conductance regulator (CFTR) gene that lead to defective ion transport in the conducting pulmonary airways and exocrine glands. Through a process that is not fully understood, CFTR defects predispose affected patients to chronic endobronchial infections with organisms such as Pseudomonas aeruginosa and Staphylococcus aureus. Following the discovery of the CFTR gene in 1989, CF became one of the primary targets for gene therapy research. Early enthusiasm surrounded the new field of gene therapy during most of the 1990s and it led academics and clinicians on a big effort to apply gene therapy for cystic fibrosis. Clinical studies have been pursued using recombinant adenovirus, recombinant adeno-associated virus, cationic liposomes, and cationic polymer vectors. Although to this date no dramatic therapeutic benefits have been observed, a lot of information has been gained from the pre-clinical and clinical studies that were performed. This learning curve has led to the optimization of vector technology and an appreciation of immune and mechanical barriers that have to be overcome for successful delivery.
Indexed as
Identifiers
18600482What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.